Patents by Inventor Gerd MANDER

Gerd MANDER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Means and methods for the determination of the biological activity of BoNT/E in cells
    Patent number: 11874273
    Abstract: The present invention pertains to a polyclonal or monoclonal antibody specifically binding to BoNT/E-cleaved SNAP-25.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: January 16, 2024
    Inventors: Cornelia Bruenn, Gerd Mander
  • MEANS AND METHODS FOR THE DETERMINATION OF THE BIOLOGICAL ACTIVITY OF BONT/E IN CELLS
    Publication number: 20210116440
    Abstract: The present invention pertains to a polyclonal or monoclonal antibody specifically binding to BoNT/E-cleaved SNAP-25.
    Type: Application
    Filed: December 15, 2020
    Publication date: April 22, 2021
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Cornelia BRUENN, Gerd MANDER
  • Means and methods for the determination of the biological activity of BoNT/E in cells
    Patent number: 10900955
    Abstract: The present invention pertains to a polyclonal or monoclonal antibody specifically binding to BoNT/E-cleaved SNAP-25.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 26, 2021
    Inventors: Cornelia Bruenn, Gerd Mander
  • Methods for enhancing the specific uptake of botulinum neurotoxins into cells
    Patent number: 10725025
    Abstract: The present invention provides a method for enhancing the specific uptake of a neurotoxin polypeptide into cells, the method comprising: incubating cells susceptible to neurotoxin intoxication with a neurotoxin polypeptide for a time and under conditions which allow for the neurotoxin polypeptide to exert its biological activity, the incubation comprising at least one of the following steps: (i) K+-mediated depolarization of the cells, (ii) a reduced neurotoxin polypeptide exposition time and/or (iii) agitation of the cells during neurotoxin polypeptide exposition, thereby enhancing the specific uptake of the neurotoxin polypeptide into said cells.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: July 28, 2020
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Claudia Jatzke, Karl-Heinz Eisele, Gerd Mander, Klaus Fink
  • MEANS AND METHODS FOR THE DETERMINATION OF THE BIOLOGICAL ACTIVITY OF BONT/E IN CELLS
    Publication number: 20190023771
    Abstract: The present invention pertains to a polyclonal or monoclonal antibody specifically binding to BoNT/E-cleaved SNAP-25.
    Type: Application
    Filed: December 18, 2015
    Publication date: January 24, 2019
    Inventors: Cornelia BRUENN, Gerd MANDER
  • METHODS FOR ENHANCING THE SPECIFIC UPTAKE OF BOTULINUM NEUROTOXINS INTO CELLS
    Publication number: 20180238861
    Abstract: The present invention provides a method for enhancing the specific uptake of a neurotoxin polypeptide into cells, the method comprising: incubating cells susceptible to neurotoxin intoxication with a neurotoxin polypeptide for a time and under conditions which allow for the neurotoxin polypeptide to exert its biological activity, the incubation comprising at least one of the following steps: (i) K+-mediated depolarization of the cells, (ii) a reduced neurotoxin polypeptide exposition time and/or (iii) agitation of the cells during neurotoxin polypeptide exposition, thereby enhancing the specific uptake of the neurotoxin polypeptide into said cells.
    Type: Application
    Filed: March 3, 2016
    Publication date: August 23, 2018
    Inventors: Claudia JATZKE, Karl-Heinz EISELE, Gerd MANDER, Klaus FINK
  • GANGLIOSIDES FOR STANDARDIZING AND INCREASING THE SENSITIVITY OF CELLS TO BOTULINUM NEUROTOXINS IN IN VITRO TEST SYSTEMS
    Publication number: 20170059558
    Abstract: The present invention pertains to a method for standardizing the sensitivity of induced pluripotent stem cell (iPS)-derived neurons to a neurotoxin polypeptide, comprising the steps of: a) cultivating different batches of induced pluripotent stem cell-derived neurons in a cell culture medium comprising GT1b for at least 3 hours; b) contacting the different batches of induced pluripotent stem cell-derived neurons of step a) with a neurotoxin polypeptide; c) cultivating the different batches of induced pluripotent stem cell-derived neurons of step b) for at least 24 hours in the presence of GT1b under conditions which allow for the neurotoxin polypeptide to exert its biological activity, thereby standardizing the sensitivity of the induced pluripotent stem cell-derived neurons to a neurotoxin polypeptide.
    Type: Application
    Filed: February 18, 2015
    Publication date: March 2, 2017
    Inventors: Karl-Heinz EISELE, Gerd MANDER